Ovid Therapeutics Inc. - 8-K Filing
On May 12, 2026, Ovid Therapeutics reported first-quarter financial results with $165.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 (excluding $27.3 million from April warrant exercises). The company raised $60.0 million in a March 2026 private placement and received $53.9 million upon full exercise of Series A warrants related to an October 2025 financing. Ovid also provided business updates, including the initiation of Phase 1 trials for OV4071 (an oral KCC2 activator) in May 2026 and plans to expand OV329 development into TSC-associated seizures and inf... (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $OVID